Last reviewed · How we verify
Cimicifuga Herbarium
Cimicifuga Herbarium is a Herbal extract / phytoestrogen Small molecule drug developed by Phytopharm Consulting Brazil. It is currently in Phase 3 development for Menopausal vasomotor symptoms (hot flashes, night sweats).
Cimicifuga (black cohosh) herbarium extract modulates estrogen receptor signaling and reduces vasomotor symptoms through phytoestrogen activity.
Cimicifuga (black cohosh) herbarium extract modulates estrogen receptor signaling and reduces vasomotor symptoms through phytoestrogen activity. Used for Menopausal vasomotor symptoms (hot flashes, night sweats).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cimicifuga Herbarium |
|---|---|
| Sponsor | Phytopharm Consulting Brazil |
| Drug class | Herbal extract / phytoestrogen |
| Modality | Small molecule |
| Therapeutic area | Women's Health / Menopause |
| Phase | Phase 3 |
Mechanism of action
Cimicifuga contains triterpene glycosides and other phytochemicals that interact with estrogen receptors and serotonin pathways, reducing hot flashes and night sweats associated with menopause. The mechanism involves both direct estrogenic effects and modulation of thermoregulatory centers in the hypothalamus.
Approved indications
- Menopausal vasomotor symptoms (hot flashes, night sweats)
Common side effects
- Gastrointestinal upset
- Headache
- Dizziness
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cimicifuga Herbarium CI brief — competitive landscape report
- Cimicifuga Herbarium updates RSS · CI watch RSS
- Phytopharm Consulting Brazil portfolio CI
Frequently asked questions about Cimicifuga Herbarium
What is Cimicifuga Herbarium?
How does Cimicifuga Herbarium work?
What is Cimicifuga Herbarium used for?
Who makes Cimicifuga Herbarium?
What drug class is Cimicifuga Herbarium in?
What development phase is Cimicifuga Herbarium in?
What are the side effects of Cimicifuga Herbarium?
Related
- Drug class: All Herbal extract / phytoestrogen drugs
- Manufacturer: Phytopharm Consulting Brazil — full pipeline
- Therapeutic area: All drugs in Women's Health / Menopause
- Indication: Drugs for Menopausal vasomotor symptoms (hot flashes, night sweats)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing